ホーム › トリプルネガティブ乳がん › カリフォルニア州 › Los Angeles
Los Angeles、CAにおけるトリプルネガティブ乳がんの臨床試験
Los Angelesとその周辺地域（約30マイル以内）の拠点で、トリプルネガティブ乳がんに関する27件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
被験者募集中第1相
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- UCLA Jonsson Comprehensive Cancer Center, Los Angeles
- USC Norris Comprehensive Cancer Center, Los Angeles
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
被験者募集中第1相
- University of California - Los Angeles, Los Angeles
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
被験者募集中第3相
- UCLA Department of Medicine - Hematology & Oncology ( Site 0047), Los Angeles
Intratumoral N17350 in Advanced Solid Tumors
被験者募集中第1/2相
- The Angeles Clinic and Research Institute, Los Angeles
- UCLA - Jonsson Comprehensive Cancer Center, Los Angeles
Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
被験者募集中第2相
- Ellison Institute of Technology (EITM), Los Angeles
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
被験者募集中第3相
- Cedars-Sinai Cancer at Beverly Hills, Los Angeles
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- USC/Norris Comprehensive Cancer Center, Los Angeles
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- USC Norris Comprehensive Cancer Center, Los Angeles
SMP-3124LP in Adults With Advanced Solid Tumors
被験者募集中第1/2相
- Cedars Sinai Medical Center, Los Angeles
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
被験者募集中第2/3相
- USC/Norris Comprehensive Cancer Center, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer
被験者募集中第1/2相
- Cedars-Sinai Medical Center, Los Angeles
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
被験者募集中第1/2相
- University of California Los Angeles Medical Center, Los Angeles
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
被験者募集中第2相
- Cedars-Sinai Medical Center, Los Angeles
- Cedars-Sinai Medical Center Beverly Hills, Los Angeles
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
被験者募集中第1相
- University of California LA, Los Angeles
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
被験者募集中第1相
- USC Norris Comprehensive Cancer Center /ID# 279603, Los Angeles
Study of XB010 in Subjects With Solid Tumors
被験者募集中第1相
- UCLA Department of Medicine - Hematology/Oncology, Los Angeles
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
被験者募集中第1相
- Start Lacn, Los Angeles
A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer
被験者募集中第1相
- USC / Norris Comprehensive Cancer Center, Los Angeles
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
被験者募集中第2相
- University of Southern California, Los Angeles
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
被験者募集中第2相
- Cedars-Sinai Medical Center, Los Angeles
Access to Genetic Testing in Underserved Patients With Cancer
被験者募集中健康なボランティア歓迎
- USC / Norris Comprehensive Cancer Center, Los Angeles
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
被験者募集中第1/2相
- Los Angeles Cancer Network (LACN) - Good Sam, Los Angeles
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
被験者募集中第1/2相
- University of Southern California, Los Angeles
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
被験者募集中第1/2相
- UCLA Medical Center, Los Angeles
A Study of NX-1607 in Adults With Advanced Malignancies
被験者募集中第1相
- University of Southern California, Los Angeles
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
被験者募集中第2相
- Valkyrie Clinical Trials, Los Angeles
他の都市におけるトリプルネガティブ乳がんの試験
- Houston, TX42件の研究
- New York City, NY31件の研究
- Nashville, TN28件の研究
- Boston, MA26件の研究
- San Antonio, TX23件の研究
- St. Louis, MO21件の研究
- Arlington, VA20件の研究
- Atlanta, GA20件の研究
- Dallas, TX18件の研究
- Chicago, IL16件の研究
- Columbus, OH16件の研究
- Grand Rapids, MI15件の研究
Los Angelesにおける他の研究
- 非小細胞肺癌87件の研究
- がん（全種類）74件の研究
- 乳がん73件の研究
- 前立腺がん61件の研究
- 大腸癌59件の研究
- 転移性癌57件の研究
- 卵巣がん50件の研究
- 肺がん45件の研究
- 頭頸部扁平上皮癌42件の研究
- 膵臓がん35件の研究
- 子宮内膜がん34件の研究
- 悪性黒色腫34件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。